Antares Pharma’s (ATRS) Buy Rating Reiterated at HC Wainwright

Antares Pharma (NASDAQ:ATRS)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Thursday. They currently have a $4.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 67.36% from the stock’s previous close.

A number of other equities analysts have also recently commented on ATRS. BidaskClub raised Antares Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. Piper Jaffray Companies set a $3.00 price target on Antares Pharma and gave the stock a “buy” rating in a report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and two have assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $3.94.

Antares Pharma (NASDAQ:ATRS) traded up $0.04 during trading on Thursday, hitting $2.39. The stock had a trading volume of 3,180,000 shares, compared to its average volume of 1,220,000. The company has a debt-to-equity ratio of 0.69, a current ratio of 3.34 and a quick ratio of 2.89. Antares Pharma has a 12 month low of $1.58 and a 12 month high of $4.09. The firm has a market cap of $373.81, a PE ratio of -21.73 and a beta of 0.30.

Several institutional investors have recently bought and sold shares of ATRS. Armistice Capital LLC raised its holdings in shares of Antares Pharma by 81.0% during the 4th quarter. Armistice Capital LLC now owns 7,600,000 shares of the specialty pharmaceutical company’s stock worth $15,124,000 after buying an additional 3,400,000 shares in the last quarter. State Street Corp grew its position in Antares Pharma by 2,682.1% during the 2nd quarter. State Street Corp now owns 2,027,650 shares of the specialty pharmaceutical company’s stock worth $6,530,000 after acquiring an additional 1,954,769 shares during the last quarter. Northern Trust Corp grew its position in Antares Pharma by 478.1% during the 2nd quarter. Northern Trust Corp now owns 1,654,266 shares of the specialty pharmaceutical company’s stock worth $5,327,000 after acquiring an additional 1,368,131 shares during the last quarter. Broadfin Capital LLC grew its position in Antares Pharma by 41.5% during the 4th quarter. Broadfin Capital LLC now owns 4,535,647 shares of the specialty pharmaceutical company’s stock worth $9,026,000 after acquiring an additional 1,329,747 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Antares Pharma by 10.1% during the 2nd quarter. Vanguard Group Inc. now owns 6,186,232 shares of the specialty pharmaceutical company’s stock worth $19,920,000 after acquiring an additional 567,144 shares during the last quarter. 34.67% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Antares Pharma’s (ATRS) Buy Rating Reiterated at HC Wainwright” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/02/15/antares-pharmas-atrs-buy-rating-reaffirmed-at-hc-wainwright.html.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply